# FY4/23 3Q IR PRESENTATION 

AIN HOLDINGS INC.
March 2023

## Results Overview

## Consolidated P/L

Net sales increased $12.5 \%$ YoY and declined 1.2\% against the plan due to new store openings and contribution of existing stores, despite the impact of the COVID-19. Ordinary profit increased 14.5\% YoY and declined $14.1 \%$ against the plan due to increase of sales.

| ( $\ddagger$ million) | $\begin{gathered} \mathrm{FY} 4 / 223 \mathrm{Q} \\ \text { results } \end{gathered}$ | $\underset{\text { plan }}{\mathrm{FY} 4 / 23 \mathrm{Q}}$ | $\begin{gathered} \mathrm{FY} 4 / 233 \mathrm{QQ} \\ \text { results } \end{gathered}$ | $\begin{gathered} \text { Yoy } \\ \text { change } \end{gathered}$ | $\begin{gathered} \text { Yor } \\ \text { change(\%) } \end{gathered}$ | $\underset{\substack{\mathrm{v}_{\mathrm{s} \text { plan }}^{(\%)}}}{ }$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 234,610 | 267,191 | 263,906 | +29,296 | +12.5 | (1.2) |
| Gross profit | 36,500 | 42,793 | 39,692 | +3,192 | +8.7 | (7.2) |
| \% of net sales | 15.6 | 16.0 | 15.0 |  |  |  |
| SG\&A expenses | 26,286 | 28,826 | 28,006 | +1,720 | +6.5 | (2.8) |
| \% of net sales | 11.2 | 10.8 | 10.6 |  |  |  |
| Operating profit | 10,214 | 13,967 | 11,685 | +1,471 | +14.4 | (16.3) |
| \% of net sales | 4.4 | 5.2 | 4.4 |  |  |  |
| Ordinary profit | 10,800 | 14,390 | 12,367 | +1,567 | +14.5 | (14.1) |
| \% of net sales | 4.6 | 5.4 | 4.7 |  |  |  |
| Profit attributable to owners of parent | 6,231 | 7,703 | 6,628 | +397 | +6.4 | (14.0) |
| \% of net sales | 2.7 | 2.9 | 2.5 |  |  |  |
| Earnings per share ( $¥$ ) | 176.89 | 219.29 | 188.70 | +11.81 | +6.7 | (13.9) |

Figures in the table are rounded down

## Dispensing Pharmacy Business (Consolidated)

Net sales increased $12.7 \%$ YoY and declined $1.2 \%$ against the plan due to new store openings including M\&A and contribution of stores opened previous year. Segment profit increased $1.3 \%$ YoY and declined $14.4 \%$ against the plan.

|  | FY4/22 3Q <br> results | FY4/23 3Q <br> plan | FY4/23 3Q <br> results | Yoy <br> change | Yor <br> change(\%) | Vs plan <br> (\%) |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| ( million) |  |  |  |  |  |  |

Figures in the table are rounded down

## Cosmetic and Drug Store Business (Consolidated)

Net sales up $23.2 \%$ YoY and $0.4 \%$ against the plan due to the recovery of existing stores and contribution of stores opened in previous year despite the impact of the COVID-19. Segment profit was $¥ 737$ million, $¥ 672$ million above the plan.

| ( $\ddagger$ million) | $\begin{gathered} \text { FY4/22 } 3 \mathrm{Q} \\ \text { results } \end{gathered}$ | $\begin{gathered} \mathrm{FY} 4 / 233 \mathrm{Q} \\ \text { plan } \\ \hline \end{gathered}$ | $\begin{gathered} \mathrm{FY} 4 / 233 \mathrm{Q} \\ \text { results } \end{gathered}$ | YoY change | $\begin{gathered} \text { YoY } \\ \text { change(\%) } \end{gathered}$ | Vs plan (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 15,286 | 18,761 | 18,836 | +3,550 | +23.2 | +0.4 |
| Gross profit | 5,170 | 6,998 | 7,102 | +1,932 | +37.4 | +1.5 |
| \% of net sales | 33.8 | 37.3 | 37.7 |  |  |  |
| SG\&A expenses | 6,693 | 6,933 | 6,401 | (292) | (4.4) | (7.7) |
| \% of net sales | 43.8 | 37.0 | 34.0 |  |  |  |
| Operating profit | $(1,522)$ | 65 | 700 | +2,222 | - | +976.9 |
| \% of net sales | - | 0.3 | 3.7 |  |  |  |
| Segment profit | $(1,474)$ | 65 | 737 | +2,211 |  | +1,033.8 |
| \% of net sales | - | 0.3 | 3.9 |  |  |  |
| Number of stores | 74 | 82 | 76 | +2 | +2.7 | (7.3) |

Figures in the table are rounded down

## Consolidated B/S

Net cash became $¥ 36,041$ million and shareholders' equity ratio became $53.9 \%$. We are maintaining a sound financial structure even under the ongoing COVID-19 situation.

| End-FY4/22 ( $\ddagger$ million) |  |  |  | End-FY4/23 3Q |  |  | ( $¥$ million) |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Assets |  | Liabilities |  | Assets |  | Liabilities |  |
| Current assets <br> Cash on hand and in banks | $\begin{array}{r} 100,765 \\ 59,729 \end{array}$ | Current liabilities Short-term debt | $\begin{array}{r} 81,805 \\ 2,643 \end{array}$ | Current assets <br> Cash on hand and in banks | $\begin{array}{r} 95,490 \\ 46,193 \end{array}$ | Current <br> liabilities Short-term debt | $\begin{array}{r} 92,823 \\ 4,036 \end{array}$ |
| Fixed assets Goodwill | $\begin{array}{r} 111,696 \\ 36,352 \end{array}$ | Long-term liabilities Long-term debt | $\begin{array}{r} 11,645 \\ 5,815 \end{array}$ | Fixed assets <br> Goodwill | $\begin{array}{r} 134,072 \\ 47,539 \end{array}$ | Long-term liabilities Long-term debt | $\begin{array}{r} 12,995 \\ 5,816 \end{array}$ |
| Deferred assets |  | Total net assets | 119,010 | Deferred assets |  | Total net assets | 123,743 |
| Total assets | 212,461 | Total liabilities and net assets | 212,461 | Total assets | 229,562 | Total liabilities and net assets | 229,562 |
| Net cash |  |  | 51,030 | Net cash |  |  | 36,041 |
| Shareholders' equity ratio(\%) |  |  | 56.0 | Shareholders ratio(\%) | ' equity |  | 53.9 |

Figures in the table are rounded down
Net cash = Cash on hand and in banks - Interest-bearing debt

## Assets

The balance of total assets increased $¥ 17,101$ million from the end of the previous fiscal year due to decrease of cash on hand and in banks and increase of inventories and goodwill.

| ( $¥$ million) | End-FY4/22 3Q | End-FY4/22 | End-FY4/23 3Q | Change |
| :---: | :---: | :---: | :---: | :---: |
| Cash on hand and in banks | 55,641 | 59,729 | 46,193 | $(13,536)$ |
| Notes and accounts receivable | 10,707 | 10,110 | 11,269 | +1,159 |
| Inventories | 16,972 | 14,790 | 23,629 | +8,839 |
| Total current assets | 94,837 | 100,765 | 95,490 | $(5,275)$ |
| Buildings and structures, net | 17,984 | 17,512 | 20,591 | +3,079 |
| Land | 8,745 | 8,581 | 10,584 | +2,003 |
| Total property, plant and equipment | 30,634 | 30,636 | 38,519 | +7,883 |
| Goodwill | 38,172 | 36,352 | 47,539 | +11,187 |
| Total intangible fixed assets | 42,617 | 41,219 | 53,110 | +11,891 |
| Investments in securities | 3,204 | 2,503 | 2,938 | +435 |
| Deferred tax assets | 4,614 | 5,319 | 6,118 | +799 |
| Deposits and guarantees | 22,893 | 22,785 | 24,823 | +2,038 |
| Total investments and other assets | 39,904 | 39,840 | 42,443 | +2,603 |
| Total fixed assets | 113,157 | 111,696 | 134,072 | +22,376 |
| Total deferred assets | - | - | - | - |
| Total assets | 207,994 | 212,461 | 229,562 | +17,101 |

Figures in the table are rounded down $>$ Change:End-FY4/23 3Q compared with End-FY4/22
$>$ Capital expenditures (Property, plant and equipment and intangible fixed assets + Deposits and guarantees) totaled $¥ 11,216$ million

## Liabilities and Net Assets

Accounts payable increased $¥ 10,216$ million due to new store openings including M\&A. Shortterm and long-term debt increased $¥ 1,394$ million.

| ( $¥$ million) | End-FY4/22 3Q | End-FY4/22 | End-FY4/23 3Q | Change |
| :--- | ---: | ---: | ---: | ---: |
| Accounts payable | 52,276 | 50,756 | 60,972 | $+10,216$ |
| Short-term debt | 2,746 | 2,643 | 4,036 | $+1,393$ |
| Total current liabilities | $\mathbf{7 7 , 9 9 1}$ | $\mathbf{8 1 , 8 0 5}$ | $\mathbf{9 2 , 8 2 3}$ | $\mathbf{+ 1 1 , 0 1 8}$ |
| Long-term debt | 6,100 | 5,815 | 5,816 | +1 |
| Total long-term liabilities | $\mathbf{1 1 , 8 8 9}$ | $\mathbf{1 1 , 6 4 5}$ | $\mathbf{1 2 , 9 9 5}$ | $\mathbf{+ 1 , 3 5 0}$ |
| Total liabilities | $\mathbf{8 9 , 8 8 1}$ | $\mathbf{9 3 , 4 5 0}$ | $\mathbf{1 0 5 , 8 1 9}$ | $\mathbf{+ 1 2 , 3 6 9}$ |
| Common stock | 21,894 | 21,894 | 21,894 | - |
| Capital surplus | 20,500 | 20,500 | 20,504 | +4 |
| $\quad$ Retained earnings | 77,800 | 78,661 | 83,357 | $+4,696$ |
| Total shareholders' equity | $\mathbf{1 1 8 , 1 7 7}$ | $\mathbf{1 1 9 , 0 3 8}$ | $\mathbf{1 2 3 , 7 5 6}$ | $\mathbf{+ 4 , 7 1 8}$ |
| Total net assets | $\mathbf{1 1 8 , 1 1 3}$ | $\mathbf{1 1 9 , 0 1 0}$ | $\mathbf{1 2 3 , 7 4 3}$ | $\mathbf{+ 4 , 7 3 3}$ |
| Total liabilities and net | $\mathbf{2 0 7 , 9 9 4}$ | $\mathbf{2 1 2 , 4 6 1}$ | $\mathbf{2 2 9 , 5 6 2}$ | $\mathbf{+ 1 7 , 1 0 1}$ |
| assets |  |  |  |  |

Figures in the table are rounded down

Revised plan

## FY4/23 Revised Plan (Consolidated)

Although sales and profit in the cosmetic and drug store business achieved plan, the recovery in the number of prescriptions in the dispensing pharmacy business is slower than initially expected. The group revised the plan, net sales increase 13.2\% YoY and ordinary profit increase $12.4 \%$ YoY.

| ( $¥$ million) | FY4/22 results | $\begin{gathered} \text { FY4/23 } \\ \text { initial plan } \end{gathered}$ | FY4/23 revised plan | YoY Change(\%) | Vs initial plan change (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 316,247 | 363,000 | 358,000 | +13.2 | (1.4) |
| Gross profit | 49,971 | 58,720 | 54,870 | +9.8 | (6.6) |
| \% of net sales | 15.8 | 16.2 | 15.3 |  |  |
| SG\&A expenses | 34,832 | 38,720 | 37,690 | +8.2 | (2.7) |
| \% of net sales | 11.0 | 10.7 | 10.5 |  |  |
| Operating profit | 15,139 | 20,000 | 17,180 | +13.5 | (14.1) |
| \% of net sales | 4.8 | 5.5 | 4.8 |  |  |
| Ordinary profit | 16,041 | 20,500 | 18,030 | +12.4 | (12.0) |
| \% of net sales | 5.1 | 5.6 | 5.0 |  |  |
| Profit attributable to owners of parent | 7,092 | 11,000 | 9,000 | +26.9 | (18.2) |
| \% of net sales | 2.2 | 3.0 | 2.5 |  |  |
| Earnings per share( $¥$ ) | 201.47 | 313.15 | 256.20 | +27.2 | (18.2) |
| Annual dividend ( $¥$ ) | 55.00 | 60.00 | 60.00 | +9.1 | 0.0 |
| Figures in the table are rounded down |  | YoY Change: FY4/23 revised plan compared with FY4/22 results |  |  |  |

## FY4/23 Revised Plan (Dispensing Pharmacy Business )

| ( $¥$ million) | FY4/22 results | $\begin{gathered} \text { FY4/23 } \\ \text { initial plan } \end{gathered}$ | $\begin{aligned} & \mathrm{FY} 4 / 23 \\ & \text { revised plan } \end{aligned}$ | YoY Change(\%) | Vs initial plan change (\%) |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Net sales | 283,111 | 326,000 | 321,560 | +13.6 | (1.4) |
| Gross profit | 38,194 | 44,920 | 41,350 | +8.3 | (7.9) |
| \% of net sales | 13.5 | 13.8 | 12.9 |  |  |
| SG\&A expenses | 13,875 | 16,080 | 16,620 | +19.8 | +3.4 |
| \% of net sales | 4.9 | 4.9 | 5.2 |  |  |
| Operating profit | 24,319 | 28,840 | 24,730 | +1.7 | (14.3) |
| \% of net sales | 8.6 | 8.8 | 7.7 |  |  |
| Segment profit | 25,082 | 29,360 | 25,520 | +1.7 | (13.1) |
| \% of net sales | 8.9 | 9.0 | 7.9 |  |  |
| Number of pharmacies | 1,099 | 1,249 | 1,210 | +10.1 | (3.1) |

Figures in the table are rounded down
YoY Change: FY4/23 revised plan compared with FY4/22 results

## FY4/23 Revised Plan (Cosmetic and Drug Store Business)

|  | FY4/22 <br> results | FY4/23 <br> initial plan | FY4/23 <br> revised plan |  | YoY <br> Change(\%) | Vs initial plan <br> change (\%) |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net salles | 20,558 | 24,727 | 24,920 | +21.2 | +0.8 |  |
| Gross profit | 7,030 | 9,350 | 9,410 | +33.9 | +0.6 |  |
| \% of net sales | 34.2 | 37.8 | 37.8 |  |  |  |
| SG\&A expenses | 8,858 | 9,250 | 8,570 | $(3.3)$ | $(7.4)$ |  |
| \% of net sales | 43.1 | 37.4 | 34.4 |  |  |  |
| Operating profit | $(1,827)$ | 100 | 840 | - | +740.0 |  |
| \% of net sales | - | 0.4 | 3.4 |  |  |  |
| Segment profit | $(1,764)$ | 100 | 880 | - | +780.0 |  |
| \% of net sales | - | 0.4 | 3.5 |  |  |  |
| Number of | 78 | 83 | 78 | 0.0 | $(6.0)$ |  |
| stores |  |  |  |  |  |  |

Figures in the table are rounded down
YoY Change: FY4/23 revised plan compared with FY4/22 results

## Inquiries related to this presentation should be addressed to

## AIN HOLDINGS INC. Corporate Planning Division TEL(81)11-814-0010 FAX(81)11-814-5550 https://www.ainj.co.jp/

This document may not be reproduced or distributed to any third party without prior approval of AIN HOLDINGS INC. This document has been prepared for information purpose only and does not form part of a solicitation to sell or purchase any securities. Information contained herein may be changed or revised without prior notice. This document may contain forecasting statements as to future results of operations. No forecast statement can be guaranteed and actual results of operations may differ from those projected.

